De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”
- 18 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 92 (10), 1309-1318
- https://doi.org/10.1007/s00277-013-1780-7
Abstract
We report the final results of a prospective trial testing the combination of fludarabine, Ara-C and idarubicin (FLAI) followed by low-dose gemtuzumab ozogamicin (FLAI-GO) in 85 patients aged 60 years or more with CD33+ acute myeloid leukaemia (AML). Median age was 68 years (60–82); karyotype was unfavourable in 21 patients (24 %), intermediate in 63 (74 %) and favourable in 1 (2 %). There were five therapy-related deaths. Of the 80 evaluable patients, 47 achieved complete response (CR) (58 %); CR rates were 65 and 32 % in good-intermediate/poor karyotype patients, respectively. Median length of CR was 7 months (3–76). The cumulative incidence of relapse was 84 % with an actuarial survival of 50.3 % at 1 year and 14.4 % at 2 years. The study control population is an unselected consecutive historic cohort of 104 patients treated with the FLAI regimen, who were matched for age and prognostic factors. CR rates after FLAI-GO and FLAI were comparable. However, patients with de novo AML and intermediate–favourable karyotype receiving GO had a significantly lower risk of relapse at 2 years as compared to patients not receiving GO (n = 77) (40 vs 80 %, p = 0.01) and significantly better disease-free survival (p = 0.018) and overall survival (p = 0.022).Keywords
This publication has 38 references indexed in Scilit:
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- Treatment of Unfit Patients With Acute Myeloid Leukemia: A Still Open Clinical ChallengeClinical Lymphoma Myeloma and Leukemia, 2011
- Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center StudyJournal of Clinical Oncology, 2010
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaThe New England Journal of Medicine, 2009
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid LeukemiaThe New England Journal of Medicine, 2008
- Age and acute myeloid leukemiaBlood, 2006
- Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous LeukemiaLeukemia & Lymphoma, 1993
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood, 1991
- Treatment of acute myelocytic leukemia: a study by cancer and leukemia group BBlood, 1981
- Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemiaLeukemia Research, 1979